title: Hyperfractionated radiotherapy with concurrent docetaxel for advanced head and neck cancer: a phase II study.
abstract: OBJECTIVE
  To evaluate the value of hyperfractionated radiotherapy with concurrent use of low-dose docetaxel in locally-advanced head and neck squamous cell cancer (HNSCC).
  
  
  METHODS
  Patients eligible for this study had confirmed diagnosis of HNSCC stages II (>10 cm(3)) to IVB. Radiotherapy was delivered twice daily at 1.2 Gy/fraction to a total dose of 72.0 Gy. Docetaxel (10 mg/m(2)) was administered weekly during radiotherapy.
  
  
  RESULTS
  From March 2003 to October 2008, 70 patients were treated. Primary sites included the oropharynx (n=25), hypopharynx (n=24), larynx (n=18), and other sites (n=3). Major grade 3 acute toxicities included mucositis (n=43) and treatment-related pain (n=20). The median follow-up period for surviving patients was 43 months. The 5-year local control rate and overall survival rate were 62.6% and 61.6%, respectively.
  
  
  CONCLUSIONS
  This modality is a valuable treatment option for the management of locally-advanced HNSCC.
authors.affiliation: Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan. kkarasaw@nirs.go.jp
authors.forename: Kumiko
authors.initials: K
authors.lastname: Karasawa
authors.forename: Fumihiko
authors.initials: F
authors.lastname: Matsumoto
authors.forename: Sin
authors.initials: S
authors.lastname: Ito
authors.forename: Sinichi
authors.initials: S
authors.lastname: Oba
authors.forename: Tomohisa
authors.initials: T
authors.lastname: Furuya
authors.forename: Hisako
authors.initials: H
authors.lastname: Hirowatari
authors.forename: Hiromi
authors.initials: H
authors.lastname: Izawa
authors.forename: Kana
authors.initials: K
authors.lastname: Ito
authors.forename: Keisuke
authors.initials: K
authors.lastname: Sasai
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D059248:Chemoradiotherapy / Q000379:methods; D000077143:Docetaxel; D019583:Dose Fractionation, Radiation; D004305:Dose-Response Relationship, Drug; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage*; D000077195:Squamous Cell Carcinoma of Head and Neck; D043823:Taxoids / Q000008:administration & dosage*
chemical_list: D000970:Antineoplastic Agents; D011838:Radiation-Sensitizing Agents; D043823:Taxoids; D000077143:Docetaxel